Booming Moderna expands HQ in Cambridge, MA; Vertex maps regulatory timeline for CF combo;

@FierceBiotech: Industry Voices: Clinical trial transparency--time for some carrot as well as more stick? Feature | Follow @FierceBiotech

@JohnCFierce: Danish biotech Egalet pitches $69M IPO on Nasdaq. News | Follow @JohnCFierce

@DamianFierce: Fresh off a staggering FDA rejection, Wright is spending $80M on an implant outfit. Story | Follow @DamianFierce

@EmilyMFierce: AstraZeneca, Harvard's Wyss Institute partner to advance 'Organs-on-Chips' drug-testing tech. Item | Follow @EmilyMFierce

> Armed with a major league partnership with AstraZeneca ($AZN) and a new $25 million grant from DARPA, a booming Moderna Therapeutics has expanded its headquarters in Cambridge, MA, as it builds a staff of 100 by the end of this year. Release

> In an update out today, Vertex ($VRTX) reports that it expects to see Phase III data for its Kalydeco/VX-809 combo for cystic fibrosis in mid-2014 and plans to file for an approval soon after in the U.S. and Europe. Both drugs have been tapped as "breakthrough" therapies by the FDA. Release

> Actelion ($ATLN) reported rising sales of Tracleer as regulators get closer to an expected approval of the next-gen PAH therapy Opsumit. A decision from the FDA is due this week. Story

Medical Device News

@FierceMedDev: Roche ekes out diagnostics growth as diabetes biz falters. More | Follow @FierceMedDev

@MarkHFierce: Another J&J hip lawsuit is settled. Will the company resolve the 11,000-plus suits that remain outstanding? Story | Follow @MarkHFierce

@MichaelGFierce: Trending from FierceDrugDelivery: Mini-pancreas grown from stem cells has implications for future  delivery. Article | Follow @MichaelGFierce

> Roche will close 454 Life Sciences and stop making its gene sequencing tech. Item

> Wright buying implant outfit for $80M with eye on Europe. News

> Quest blames outside factors for lowering already diminished 2013 expectations. More

> Device tax repeal fight fails again as government funding bill avoids the issue. Article

Pharma News

@FiercePharma: Top news yesterday: Teva halts Israeli layoffs amid pressure from labor, gov't. Report | Follow @FiercePharma

@CarlyHFierce: Eisai to recruit 200 new sales reps for amped-up Belviq push. ICYMI yesterday | Follow @CarlyHFierce

> FDA experts vote against expansion of Amarin's Vascepa. News

> Pharma dealmakers, listen up: Ireland may close a popular tax loophole. Story

> Roche CEO scuttles Novartis merger talk. More

Pharma Manufacturing News

@EricPFierce: Another gut check for Amarin and its fish oil drug  panel votes against wider use. News | Follow @EricPFierce

> In turnabout, U.K. tells Wockhardt to recall 5 drugs. Report

> Federal case over drug shortage comes to an end. Story

> Teva reconsiders production cuts in Israel. Item

> B. Braun recalls product after organic particulate found. More

> Genzyme expanding U.S. plant opened last year. Article

Vaccines News

> Cost of rabies vaccine limiting use in Africa. Report

> Merck, Sanofi report on first vaccine in European pilot project. More

> IOM releases modeling software for vaccine prioritization. Item

> Novartis cuts jobs in California as eastward shift continues. More

> India to expand use of pentavalent vaccine after safety thumbs-up. Article

> U.K. court orders sisters to receive MMR vaccine. Story

And Finally... H7N9 avian flu has resurged. Item

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.